Prognosis and chemotherapy drug sensitivity in liver hepatocellular carcinoma through a disulfidptosis-related lncRNA signature.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Carcinoma, Hepatocellular* ; RNA, Long Noncoding* ; Liver Neoplasms*; Humans ; Prognosis

Disulfidptosis, a new type of regulated cell death associated with the actin cytoskeleton, provides a new therapeutic tool for cancers. The direct relationship between disulfidptosis-related lncRNAs(DRLs) in liver hepatocellular carcinoma(HCC) remains unclear. We acquired transcriptomic data, corresponding clinical data, and tumor mutation data of HCC from the TCGA database. First of all, DRLs were determined through correlation analysis. Then, a prognostic model containing six DRLs was created by adopting univariate Cox regression, LASSO algorithm and multivariate Cox regression analysis. Based on the model, 424 HCC patients were divided into high- and low-risk groups. Next, we structured ROC curves and PCA through combining the model and clinical data. Enrichment analysis and immune infiltration analysis were adopted to further explore the relationship between the model and prognosis. In addition, we explored the relationship between the model and tumor mutation burden (TMB). There were significant differences between high- and low- risk groups, and patients in the high-risk group showed poor prognosis. Enrichment analysis suggested that metabolic progress was obviously different between the two groups. According to the analysis of immune infiltration, there were several differences in immune cells, function, and checkpoints. Patients with high-risk and high TMB demonstrated the least favorable prognosis. The two risk groups both manifested visiblly in chemotherapy drug sensitivity. To sum up, we set up a DRL-based signature and that may provide a predictable value for the prognosis and use of chemotherapy drugs for HCC patients.
(© 2024. The Author(s).)

Nucleic Acids Res. 2019 Jan 8;47(D1):D590-D595. (PMID: 30321428)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Cancer Cell Int. 2022 Sep 29;22(1):296. (PMID: 36175889)
Life (Basel). 2023 Jul 13;13(7):. (PMID: 37511932)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Semin Liver Dis. 2007 Feb;27(1):55-76. (PMID: 17295177)
Nat Cell Biol. 2023 Mar;25(3):404-414. (PMID: 36747082)
Zhonghua Zhong Liu Za Zhi. 2023 Mar 23;45(3):212-220. (PMID: 36944542)
Nat Rev Mol Cell Biol. 2020 Mar;21(3):123-136. (PMID: 32020081)
J Exp Clin Cancer Res. 2023 Apr 27;42(1):103. (PMID: 37101248)
Biochem Genet. 2022 Dec;60(6):1914-1933. (PMID: 35138470)
Front Genet. 2022 Jul 22;13:947551. (PMID: 35938003)
Genomics. 2013 Aug;102(2):74-83. (PMID: 23583669)
Mol Ther Nucleic Acids. 2022 Jan 25;27:1036-1055. (PMID: 35228898)
Lancet. 2018 Mar 31;391(10127):1301-1314. (PMID: 29307467)
Front Pharmacol. 2023 Feb 09;14:1088993. (PMID: 36843949)
Nat Rev Cancer. 2006 Sep;6(9):674-87. (PMID: 16929323)
Nat Rev Drug Discov. 2022 Feb;21(2):141-162. (PMID: 34862480)
Mol Cell Biochem. 2023 Sep;478(9):1899-1914. (PMID: 36583796)
Oncol Lett. 2021 Nov;22(5):773. (PMID: 34589152)
Cancer Biol Ther. 2023 Dec 31;24(1):2198904. (PMID: 37211864)
Genes Dis. 2023 Apr 18;10(5):1799-1801. (PMID: 37492701)
Pathol Res Pract. 2022 Aug;236:153958. (PMID: 35679752)
J Oncol. 2022 Sep 26;2022:3102743. (PMID: 36199800)
J Obstet Gynaecol. 2023 Dec;43(1):2181060. (PMID: 36972141)
J Exp Clin Cancer Res. 2023 May 31;42(1):137. (PMID: 37259067)
Genomics. 2020 Nov;112(6):4827-4841. (PMID: 32890701)
Front Cell Dev Biol. 2021 Aug 06;9:688751. (PMID: 34422811)
J Cell Mol Med. 2021 Jan;25(1):4-14. (PMID: 33216456)
Nature. 2009 Mar 12;458(7235):223-7. (PMID: 19182780)
Protein Cell. 2021 Aug;12(8):599-620. (PMID: 33000412)
PeerJ. 2020 Jan 17;8:e8383. (PMID: 31988807)

Keywords: Disulfidptosis; Drug sensitivity; HCC; Long noncoding RNA; Prognostic signature

0 (RNA, Long Noncoding)

Date Created: 20240327 Date Completed: 20240328 Latest Revision: 20240329

20240329

PMC10965927

10.1038/s41598-024-57954-7

38531953